title: Phase II trial of ifosfamide in recurrent and metastatic head and neck cancer.
abstract: Thirty-six patients with recurrent carcinoma of the head and neck and no prior exposure to chemotherapy were treated with Ifosfamide. This drug was administered, concomitantly with Mesna, as a 24-hr infusion at a dose of 5-6.25 g/m2 every 3 weeks. Objective activity in 32 evaluable patients was 28% (9/32, 95% C.I. 17%-39%); 40% of patients had leukocyte values less than 2000 mm3 and 6% platelets less than 50,000 mm3. Nonhematologic toxicity consisted mainly of nausea/vomiting (66% greater than or equal to grade 2) and alopecia (80% greater than or equal to grade 2). The activity encountered warrants further studies with this drug in head and neck cancer.
authors.affiliation: Servicio de Oncología Médica, Hospital General de Asturias, Oviedo, Spain.
authors.forename: J M
authors.initials: JM
authors.lastname: Buesa
authors.forename: R
authors.initials: R
authors.lastname: Fernández
authors.forename: E
authors.initials: E
authors.lastname: Esteban
authors.forename: E
authors.initials: E
authors.lastname: Estrada
authors.forename: F J
authors.initials: FJ
authors.lastname: Barón
authors.forename: I
authors.initials: I
authors.lastname: Palacio
authors.forename: M
authors.initials: M
authors.lastname: Gracia
authors.forename: A J
authors.initials: AJ
authors.lastname: Lacave
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002277:Carcinoma / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D004341:Drug Evaluation; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D007069:Ifosfamide / Q000009:adverse effects / Q000627:therapeutic use*; D007958:Leukocyte Count; D008297:Male; D015080:Mesna / Q000008:administration & dosage; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D010976:Platelet Count; D015996:Survival Rate
chemical_list: D015080:Mesna; D007069:Ifosfamide